No abstract

No abstract

We present spectroscopic observations of the AndXII dwarf spheroidal galaxy using DEIMOS/Keck-II, showing it to be moving rapidly through the Local Group (-556 km/s heliocentric velocity, -281 km/s relative to Andromeda), falling into the Local Group from ∼115 kpc beyond Andromeda's nucleus. AndXII therefore represents a dwarf galaxy plausibly falling into the Local Group for the first time, and never having experienced a dense galactic environment. From Green Bank Telescope observations, a limit on the HI gas mass of < 3 × 10 3 M ⊙ suggests that AndXII's gas could have been removed prior to experiencing the tides of the Local Group galaxies. Orbit models suggest the dwarf is close to the escape velocity of M31 for published mass models. AndXII is our best direct evidence for the late infall of satellite galaxies, a prediction of cosmological simulations.

The detection of measurable residual disease (MRD) has become a key investigation that plays a role in the prognostication and management of several hematologic malignancies. Acute myeloid leukemia (AML) is the most common acute leukemia in adults and the role of MRD in AML is still emerging. Prognostic markers are complex, largely based upon genetic and cytogenetic aberrations. MRD is now being incorporated into prognostic models and is a powerful predictor of relapse. While PCR-based MRD methods are sensitive and specific, many patients do not have an identifiable molecular marker. Immunophenotypic MRD methods using multiparametric flow cytometry (MFC) are widely applicable, and are based on the identification of surface marker combinations that are present on leukemic cells but not normal hematopoietic cells. Current techniques include a “different from normal” and/or a “leukemia-associated immunophenotype” approach. Limitations of MFC-based MRD analyses include the lack of standardization, the reliance on a high-quality marrow aspirate, and variable sensitivity. Emerging techniques that look to improve the detection of leukemic cells use dimensional reduction analysis, incorporating more leukemia specific markers and identifying leukemic stem cells. This review will discuss current methods together with new and emerging techniques to determine the role of MFC MRD analysis.